Biogen’s RA Long Shot Fails In Phase IIb
This article was originally published in The Pink Sheet Daily
Executive Summary
TNF cytokine blocker could work in other diseases.
You may also be interested in...
Despite Strategic Review, Biogen Idec To Remain Independent
The biotech has not received “any definitive offers.”
Biogen First-In-Class Baminercept Shows Benefits For RA Patients In Phase IIa
Dual mechanism lymphotoxin-ß/LIGHT pathway inhibitor demonstrates a 60 percent improvement in swollen joints after 35 days.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf